CN104603151A - 与dll-4结合的抗原结合蛋白 - Google Patents

与dll-4结合的抗原结合蛋白 Download PDF

Info

Publication number
CN104603151A
CN104603151A CN201380028998.XA CN201380028998A CN104603151A CN 104603151 A CN104603151 A CN 104603151A CN 201380028998 A CN201380028998 A CN 201380028998A CN 104603151 A CN104603151 A CN 104603151A
Authority
CN
China
Prior art keywords
seq
variable domain
chain variable
dll
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201380028998.XA
Other languages
English (en)
Chinese (zh)
Inventor
埃德维吉·格罗斯
张延良
周贺钺
兰迪·加斯特沃特
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sorrento Therapeutics Inc
Original Assignee
Sorrento Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sorrento Therapeutics Inc filed Critical Sorrento Therapeutics Inc
Publication of CN104603151A publication Critical patent/CN104603151A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN201380028998.XA 2012-05-31 2013-05-28 与dll-4结合的抗原结合蛋白 Pending CN104603151A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261654019P 2012-05-31 2012-05-31
US61/654,019 2012-05-31
PCT/US2013/042912 WO2014062245A2 (en) 2012-05-31 2013-05-28 Antigen binding proteins that bind dll-4

Publications (1)

Publication Number Publication Date
CN104603151A true CN104603151A (zh) 2015-05-06

Family

ID=49670535

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201380028998.XA Pending CN104603151A (zh) 2012-05-31 2013-05-28 与dll-4结合的抗原结合蛋白

Country Status (7)

Country Link
US (2) US10174107B2 (enExample)
EP (1) EP2855523A4 (enExample)
JP (1) JP2015520172A (enExample)
CN (1) CN104603151A (enExample)
CA (1) CA2874979A1 (enExample)
HK (1) HK1206038A1 (enExample)
WO (1) WO2014062245A2 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3485908B1 (en) 2009-10-16 2021-08-18 Mereo BioPharma 5, Inc. Therapeutic combination and use of dll4 antagonist antibodies and anti-hypertensive agents
HRP20190044T1 (hr) 2011-09-23 2019-02-22 Oncomed Pharmaceuticals, Inc. Agensi koji vežu vegf/dll4 i njihove uporabe
JP2015520172A (ja) 2012-05-31 2015-07-16 ソレント・セラピューティクス・インコーポレイテッドＳｏｒｒｅｎｔｏ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． Ｄｌｌ−４に結合する抗原結合蛋白質
KR20170029490A (ko) 2014-07-11 2017-03-15 제넨테크, 인크. 노치 경로 억제
MX382902B (es) 2014-10-31 2025-03-13 Oncomed Pharm Inc Inhibidor de la vía noth en combinación con un agente inmunoterapéutico para usarse en el tratamiento de cáncer.
AR105444A1 (es) 2015-07-22 2017-10-04 Sorrento Therapeutics Inc Anticuerpos terapéuticos que se unen a la proteína codificada por el gen de activación de linfocitos 3 (lag3)
WO2017053705A1 (en) 2015-09-23 2017-03-30 Oncomed Pharmaceuticals, Inc. Methods and compositions for treatment of cancer
KR20210095781A (ko) 2020-01-24 2021-08-03 주식회사 에이프릴바이오 항원결합 단편 및 생리활성 이펙터 모이어티로 구성된 융합 컨스트럭트를 포함하는 다중결합항체 및 이를 포함하는 약학조성물

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008042336A2 (en) * 2006-09-29 2008-04-10 Earthworks Systems, Llc Methods of producing and recycling plastic cards
WO2008076379A2 (en) * 2006-12-14 2008-06-26 Regeneron Pharmaceuticals, Inc. Human antibodies to human delta like ligand 4
WO2010032060A1 (en) * 2008-09-19 2010-03-25 Medimmune Llc Antibodies directed to dll4 and uses thereof
US20100292312A1 (en) * 2006-06-06 2010-11-18 Genentech, Inc. Anti-dll4 antibodies and methods using same

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2275449B1 (en) * 2000-06-16 2016-09-28 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to BLyS
IL149820A0 (en) * 2002-05-23 2002-11-10 Curetech Ltd Humanized immunomodulatory monoclonal antibodies for the treatment of neoplastic disease or immunodeficiency
US7750124B2 (en) 2006-09-29 2010-07-06 Oncomed Pharmaceuticals, Inc. Anti-human DLL4 antibodies and compositions
PE20121647A1 (es) * 2009-08-29 2012-12-31 Abbvie Inc Proteinas terapeuticas de union a dll4
JP2015520172A (ja) 2012-05-31 2015-07-16 ソレント・セラピューティクス・インコーポレイテッドＳｏｒｒｅｎｔｏ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． Ｄｌｌ−４に結合する抗原結合蛋白質

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100292312A1 (en) * 2006-06-06 2010-11-18 Genentech, Inc. Anti-dll4 antibodies and methods using same
WO2008042336A2 (en) * 2006-09-29 2008-04-10 Earthworks Systems, Llc Methods of producing and recycling plastic cards
WO2008076379A2 (en) * 2006-12-14 2008-06-26 Regeneron Pharmaceuticals, Inc. Human antibodies to human delta like ligand 4
WO2010032060A1 (en) * 2008-09-19 2010-03-25 Medimmune Llc Antibodies directed to dll4 and uses thereof

Also Published As

Publication number Publication date
US10717779B2 (en) 2020-07-21
WO2014062245A3 (en) 2014-10-09
US20130323248A1 (en) 2013-12-05
JP2015520172A (ja) 2015-07-16
WO2014062245A2 (en) 2014-04-24
CA2874979A1 (en) 2014-04-24
US20190169282A1 (en) 2019-06-06
HK1206038A1 (en) 2015-12-31
US10174107B2 (en) 2019-01-08
EP2855523A2 (en) 2015-04-08
EP2855523A4 (en) 2016-02-17

Similar Documents

Publication Publication Date Title
JP7624573B2 (ja) Ｐｄ－１に結合する抗原結合蛋白質
JP7140867B2 (ja) Ｐｄ－ｌ１に結合する抗原結合性タンパク質
CN104736168B (zh) 与pd-l1结合的抗原结合蛋白
CN105050618B (zh) 与c-Met结合的抗原结合蛋白
US10717779B2 (en) Methods for blocking an interaction between notch-1 and delta-like 4 (DLL-4) by administering a DDL-4 antibody
CN105120890A (zh) 与ErbB3结合的抗原结合蛋白
CN104994872B (zh) 与igf1r结合的抗原结合蛋白
HK1238648B (zh) 與pd-1結合的抗原結合蛋白

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
AD01 Patent right deemed abandoned
AD01 Patent right deemed abandoned

Effective date of abandoning: 20181204